EDUCATION, AWARENESS, SUPPORT & ORGAN DONATION
Hepatitis C News
- Gilead Submits New Drug Application to U.S. FDA For Sofosbuvir for the Treatment of Hepatitis C
READ NEWS - As many as one in 50 people around the world is infected with some type of hepacivirus or pegivirus,
including up to 200 million with hepatitis C virus (HCV), a leading cause of liver failure and liver cancer.
READ NEWS - AMSTERDAM ‐‐ Two years after direct‐acting antiviral drugs for hepatitis C virus (HCV) infection hit the
U.S. market, anemia has been far and away their most significant adverse effect, researchers said
here.
READ NEWS - AMSTERDAM, the Netherlands — A regimen of 3 direct-acting antiviral drugs plus ritonavir and
ribavirin produced sustained virologic response rates in more than 90% of a broad range of patients
infected with hepatitis C 24 weeks after therapy, results from a new clinical trial show.
READ NEWS - Gilead Submits New Drug Application to U.S. Fda for Sofosbuvir for the Treatment Of Hepatitis C
READ NEWS - Sustained Virological Response Linked With Improved Survival for HCV Patients
READ NEWS - Adherence to hepatitis C treatment: unraveling the complexities
READ NEWS - HCV Treatment Pipeline Update
READ NEWS - The Hepatitis‐Fibromyalgia Connection
READ NEWS - Serious and Fatal Skin Reactions to Incivek
READ NEWS - Triple therapy has poor safety in cirrhotic hepatitis C
BOSTON – In patients with chronic hepatitis C virus infections and compensated cirrhosis, a combination of a direct-acting antiviral agent, pegylated interferon, and ribavirin produced high on-treatment virologic response rates ...
READ NEWS - Hepatitis C Reaching Crisis Levels; Requires Coverage for Routine Screenings
WASHINGTON, Nov. 27, 2012 -- Summit on HIV and Viral Hepatitis Charts Priorities to Accelerate Testing, Reduce Disparities in Care
READ NEWS - Abbott Announces Phase 3 Hepatitis C Program Details
Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.
READ NEWS - HCV Drug Combo Promising All on Its Own
A three-drug regimen that eliminated both standard hepatitis C drugs has yielded positive early results in hard-to-treat patients, a researcher reported.
READ NEWS
Important Notice
As the new drugs are used to treat HCV, there will be new challenges to communications between patients and their health care providers. You can help. Please take this anonymous survey that will provide information to help health care professionals address their patients' concerns and ultimately lead to improved patient care.
To view the survey, please click on this link: http://www.sceptercme.com/hepcsurvey
Upcoming 2013 Events
- The International Liver Conference (EASL)
Amsterdam, The Netherlands
April 24 - 28 - Digestive Diseases Week (DDW)
Orlando, Florida
May 19 – 22
This site complies with the HONcode standard for trustworthy health information:
verify here.
The information provided on this site is intended to support, not replace, the relationship that exists between a patient and his/her physician. Hepatitis C Association does not display commercial content or receive funding from advertising products or services.
Support line 866-437-4377
